TRPA1 antagonists
AssigneeAbbVie Inc.
InventorsRichard J. Perner, Michael E. Kort, Stanley DiDomenico, Jun Chen, Anil Vasudevan
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Claims4
A method for treating pain in a subject in need of such treatment, comprising administering therapeutically effective amount of one or more compounds selected from the group consisting of (1E,3E)-1-(6-fluoropyridin-3-yl)-2-methylpent-1-en-3-one Oxime, (1E,3E)-2-methyl-1-thien-2-ylpent-1-en-3-one Oxime, (1E,3E)-1-(6-methoxypyridin-3-yl)-2-methylpent-1-en-3-one Oxime, (1E,3E)-2-methyl-1-thien-3-ylpent-1-en-3-one Oxime, (1E,3E)-2-methyl-1-pyridin-3-ylpent-1-en-3-one Oxime, (1E,3E)-2-methyl-1-pyridin-4-ylpent-1-en-3-one Oxime, (1E,3E)-2-methyl-1-(6-methylpyridin-3-yl)pent-1-en-3-one Oxime, (1E,3E)-2-methyl-1-quinolin-3-ylpent-1-en-3-one Oxime, (1E,3E)-2-methyl-1-(4-methylpyridin-3-yl)pent-1-en-3-one Oxime, (1E,3E)-2-methyl-1-[6-(trifluoromethyl)pyridine-3-yl]pent-1-en-3-one Oxime, (1E,3E)-1-(isoquinolin-4-yl)-2-methylpent-1-en-3-one Oxime and mixtures thereof.
Dependencies are inferred from the claim text.